Quarterly ResultMay 6, 2026, 08:12 AM
UroGen Pharma Q1 Revenue +151.6% to $51.0M; Net Loss $(23.6)M
AI Summary
UroGen Pharma reported strong financial results for Q1 2026, with revenue more than doubling to $51.0 million, a 151.6% increase year-over-year. The company significantly reduced its net loss by 46.2% to $(23.6) million, improving net loss per share to $(0.47). While net cash used in operating activities increased, UroGen Pharma secured $65.3 million in proceeds from long-term debt, contributing to a healthy cash position of $111.3 million at period end.
Key Highlights
- Q1 2026 revenue surged 151.6% to $51.0 million, up from $20.3 million in Q1 2025.
- Net loss significantly improved by 46.2% to $(23.6) million, from $(43.8) million year-over-year.
- Basic and diluted net loss per share improved to $(0.47) from $(0.92) in Q1 2025.
- Gross profit increased 161.2% to $46.8 million, compared to $17.9 million in the prior year.
- Selling, general and administrative expenses rose 47.2% to $51.5 million.
- Net cash used in operating activities increased to $(45.3) million from $(42.0) million.
- Proceeds from long-term debt issuance, net, totaled $65.3 million in Q1 2026.
- Cash, cash equivalents, and restricted cash ended at $111.3 million.
Price Impact
More from URGN